Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of duloxetine and pregabalin Effects on invalidation score and depression in Patients with Fibromyalgia

Next Previous
Trial Profile

Comparison of duloxetine and pregabalin Effects on invalidation score and depression in Patients with Fibromyalgia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Duloxetine (Primary) ; Pregabalin
  • Indications Fibromyalgia
  • Focus Therapeutic Use

Most Recent Events

  • 19 Jan 2022 New trial record
  • 01 Jan 2022 Primary endpoint (Invalidation in patient with fibromyalgia.)has not been met, as per results published in the Clinical Rheumatology
  • 01 Jan 2022 Primary endpoint (Depression score in Beck depression inventory) has not been met, as per results published in the Clinical Rheumatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top